Analysts expect K2M Group Holdings Inc (NASDAQ:KTWO) to post earnings per share (EPS) of ($0.18) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for K2M Group’s earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.16). K2M Group posted earnings of ($0.30) per share during the same quarter last year, which suggests a positive year over year growth rate of 40%. The business is expected to issue its next earnings report on Monday, March 5th.

On average, analysts expect that K2M Group will report full year earnings of ($0.84) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.76). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.78) to ($0.37). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow K2M Group.

K2M Group (NASDAQ:KTWO) last released its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $62.65 million during the quarter, compared to the consensus estimate of $62.69 million. K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The business’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.19) EPS.

KTWO has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of K2M Group from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, October 4th. Piper Jaffray Companies reiterated a “buy” rating and issued a $28.00 price objective on shares of K2M Group in a research note on Thursday, September 28th. Royal Bank of Canada reiterated a “buy” rating and issued a $26.00 price objective on shares of K2M Group in a research note on Friday, September 22nd. UBS Group reiterated a “buy” rating and issued a $24.00 price objective (down previously from $26.00) on shares of K2M Group in a research note on Tuesday, October 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $27.00 price objective on shares of K2M Group in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $24.40.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC grew its position in K2M Group by 7,765.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock valued at $100,000 after purchasing an additional 4,659 shares during the period. Rockefeller Financial Services Inc. acquired a new stake in K2M Group in the 3rd quarter valued at $105,000. BNP Paribas Arbitrage SA grew its position in K2M Group by 5,175.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock valued at $109,000 after purchasing an additional 4,399 shares during the period. Dorsey & Whitney Trust CO LLC acquired a new stake in K2M Group in the 2nd quarter valued at $211,000. Finally, Trexquant Investment LP acquired a new stake in K2M Group in the 3rd quarter valued at $223,000. 97.95% of the stock is owned by institutional investors and hedge funds.

K2M Group (NASDAQ KTWO) traded up $0.11 during trading hours on Thursday, hitting $18.30. 584,698 shares of the stock traded hands, compared to its average volume of 388,467. The company has a market cap of $779.91, a price-to-earnings ratio of -19.06 and a beta of 1.34. The company has a quick ratio of 1.67, a current ratio of 3.06 and a debt-to-equity ratio of 0.29. K2M Group has a 12 month low of $16.44 and a 12 month high of $25.99.

TRADEMARK VIOLATION WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/04/brokerages-anticipate-k2m-group-holdings-inc-ktwo-to-announce-0-18-eps.html.

About K2M Group

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Get a free copy of the Zacks research report on K2M Group (KTWO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.